World Neuroscience Innovation Forum to be Held at London’s Francis Crick Institute
Partners HealthCare, a Boston-based hospital system that includes Brigham and Women’s Hospital and Massachusetts General Hospital, and whose faculty teach at Harvard Medical School, today announced the first World Neuroscience Innovation Forum, which will bring together senior corporate executives, top clinicians, venture investors, and leading researchers from the U.S. and Europe to battle diseases that afflict one in six people around the world. The Forum will take place at the Francis Crick Institute in London on March 27, 2017.
“Neurodegenerative and related diseases are among the greatest challenges confronting contemporary society and their enormous growth represent a potential economic cataclysm. This global gathering of some of the world’s top neuroscience leaders will catalyze new connections, conversations and thinking around these unprecedented challenges,” said Rudolph E. Tanzi, Ph.D., Vice-Chair of Neurology, Director of Genetics and Aging Research Unit, Massachusetts General Hospital, and Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School.
The Forum will launch the Springboard Challenge, an award competition that will seed new international, multi-sector neuroscience teams dedicated to the development of disruptive approaches to improve therapeutics and diagnostics to treat neurodegenerative (NDD) or neuroinflammatory (NID) diseases. The Challenge will offer three awards of $50,000 each and mentorship support from leading UK and US venture capitalists. The awards are intended to fund team meetings, logistics, and strategic planning efforts for the proposed solution. Collaborations enabled by the awards will seek multi-year support from Forum industry sponsors, governments, investors, foundations and other organizations. Award selections will be made in the summer of 2017.
“Alzheimer’s and other neurological diseases such as epilepsy, multiple sclerosis and Parkinson’s afflict one in six people around the world and a truly global effort is needed to combat them. The World Forum will support and enhance that effort by inspiring the kind of interactions and collaborations that can lead to life-changing products and therapies,” said Anne Klibanski, M.D., Chief Academic Officer for Partners HealthCare and the Forum’s organizer.
The Forum will feature highly interactive panel discussions on topics ranging from investment priorities to therapies to the impact of neurodegeneration on the health care system, as well as keynote sessions with Biogen and Eli Lilly.
“The complexity of discovering treatment for neurodegenerative diseases requires an innovative and collaborative approach in order to advance the knowledge we have about these conditions,” said Michael Ehlers, M.D., Ph.D., Executive Vice President, Research and Development, Biogen. “Biogen is committed to researching and developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Through our support of events like the World Neuroscience Innovation Forum, we hope to accelerate the discovery of new medicines for the people who need them.”
“Lilly is committed to battling neurodegenerative diseases,” said John C. Lechleiter, Chairman of the Board, Lilly. “The World Forum will be an important milestone in the efforts to unravel the complexity of these diseases and act on them to help millions of patients around the world.”
Sponsors of the Forum include Biogen, Lilly, GSK, Pfizer, the Francis Crick Institute, the High Lantern Group, Imperial College Health Partners, Janssen Neuroscience and MedCity.
For more information or to register, please go to http://neuroscienceinnovationforum.org/.
Partners HealthCare is a Boston-based integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is the largest academic research organization in the Unites States and a principal teaching affiliate of Harvard Medical School. Partners HealthCare is a non-profit organization.
The Francis Crick Institute is a unique partnership between the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King's College London.
Rich Copp, 617-278-1031
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar15.12.2017 22:13 | Pressemelding
Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion will now be sent to the European Commission (EC) for final review. Herzuma® is a biosimilar to Herceptin®i, a breast cancer and gastric cancer treatment antibody biologic drug developed by Genentech and marketed by Roche. Herceptin® is a blockbuster drug which had worldwide sales of CHF 6.8 billionii (US$6.8 billion) in 2016, of which CHF 2.1 billioniii (US$2.1 billion) was in
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease15.12.2017 12:34 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT), has adopted a positive opinion recommending a marketing authorization (MA) for investigational compound Cx601 (darvadstrocel). Cx601 is expected to be indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.2 This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/201712
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards15.12.2017 12:21 | Pressemelding
Bitcoin Romania, leading Eastern European Bitcoin exchange & brokerage firm, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration that allows a global clientele to acquire Bitcoin and Ethereum cryptocurrencies using Visa and Mastercard bank cards. Unprecedented in Romania, this is one of the first East-Central European integration partnerships that allow consumers to use their cards to purchase cryptocurrency. Until recently, investors could only acquire cryptocurrencies through bank transfers and cash deposits, but the volatility of cryptocurrency markets dictates the need for additional operational flexibility. Investors require faster, safer, more reliable, and more comfortable ways to complete purchases. “One minute can make the difference between a million lost and a million earned. That is pr
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum15.12.2017 11:38 | Pressemelding
A high-level delegation of dignitaries, scholars and intellectuals participating in the fourth annual Forum for Promoting Peace in Muslim Societies, visited the Louvre Abu Dhabi museum. The delegation was headed by H.E Mustafa Ceric, former Grand Mufti of Bosnia; alongside Sheikh Mohammad Mukhtar Ould Imbala, Head of Mauritania’s Fatwa & Grievances Supreme Council; H.E Amar Mirghani Hussein, Sudanese Minister of (religious) Guidance and Endowments; and H.E Salho Jay, Imam of the Juma Masjid in South Africa. The Forum was held in Abu Dhabi from 11-13 December 2017, with the participation of more than 700 scholars, intellectuals and religious dignitaries from around the world. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171215005255/en/ Group Photo of the Scholars and Intellectuals during their visit to the L
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million15.12.2017 11:00 | Pressemelding
Global real estate investment company Kennedy Wilson (NYSE: KW) announces that it has acquired Northbank Apartments, a wholly-owned 124-unit apartment community in Dublin’s North Docks, for €45 million from Jarmar Properties Limited (In Receivership) acting through David Carson of Deloitte as Statutory Receiver, the lender being the National Asset Management Agency (“NAMA”). Situated in Dublin’s North Docks, Northbank is located just 50 meters from Kennedy Wilson’s existing 84-unit Liffey Trust apartments. The two buildings benefit from great transport links as the LUAS Red line is immediately adjacent connecting to Dublin’s city centre and main train stations in five minutes. “The successful acquisition of Northbank in such close proximity to our Liffey Trust asset allows us to leverage our existing presence and implement our value-add asset management strategy, including a
AML BitCoin Enters Phase II of ICO15.12.2017 09:00 | Pressemelding
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency. This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two. HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom